Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 148.87M | 140.12M | 122.89M | 105.45M | 84.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.87M | 140.12M | 122.89M | 105.45M | 84.04M |
| Cost of Revenue | 73.85M | 68.57M | 58.18M | 46.61M | 43.96M |
| Gross Profit | 75.02M | 71.55M | 64.71M | 58.84M | 40.09M |
| SG&A Expenses | 17.77M | 12.13M | 12.42M | 10.66M | 9.23M |
| Depreciation & Amortization | 1.55M | 1.59M | 1.63M | 1.66M | 1.69M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.91M | 88.43M | 79.13M | 66.41M | 62.84M |
| Operating Income | 49.96M | 51.68M | 43.77M | 39.04M | 21.20M |
| Income Before Tax | 56.81M | 55.23M | 23.75M | -1.46M | -52.10K |
| Income Tax Expenses | 11.94M | 11.82M | 9.82M | 9.35M | 4.26M |
| Earnings from Continuing Operations | 44.87 | 43.41 | 13.92 | -10.82 | -4.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.87M | 43.41M | 13.92M | -10.82M | -4.31M |
| EBIT | 49.96M | 51.68M | 43.77M | 39.04M | 21.20M |
| EBITDA | 51.51M | 53.27M | 45.40M | 40.70M | 22.89M |
| EPS Basic | 0.04 | 0.04 | 0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.02 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 4.29B | 4.28B | 4.28B | 4.27B | 4.27B |
| Average Diluted Shares Outstanding | 4.54B | 4.42B | 4.35B | 4.27B | 4.28B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |